Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

General Discussions

FDA Approves Dasatinib for Pediatric Ph+ ALL

By Gina Columbus
General Discussions - Discussions
6 replies
The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

The approval was based on findings from a single cohort of the phase II CA180-372 trial (NCT01460160), which demonstrated a 3-year event-free survival (EFS) binary rate of 64.1% (95% CI, 52.4%-74.7%) in 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.

“As treatments have advanced in recent years, we’ve seen improvements in outcomes for pediatric patients with Ph+ ALL overall, but there remains a need for additional options,” said Stephen Hunger, MD, lead study author, chief of the division of oncology and director of the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia, in a press release. “The phase II CA180-372 trial was particularly informative because it was designed to limit the use of cranial irradiation and stem cell transplant. In the study, Sprycel plus chemotherapy demonstrated a three-year event-free survival benefit. These results show that Sprycel is an effective medication for physicians to consider for children and adolescents with Ph+ ALL.”

In the phase II study, 106 patients aged <18 years old were treated with continuous daily dasatinib starting at day 15 of induction chemotherapy. The 78 patients evaluated for efficacy in cohort 1 received dasatinib at 60 mg/m2 daily for up to 2 years in combination with a backbone chemotherapy regimen of the AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol. Additionally, patients were assigned to receive stem cell transplant based on minimal residual disease if they were considered high-risk.

Results showed that a complete remission was achieved by all treated patients. At day 78 (end of first block of treatment), patients with minimal residual disease (MRD) ≥0.05% were eligible for hematopoietic stem cell transplantation (HSCT) in first remission, as were patients with MRD 0.005% to 0.05% who were still MRD-positive following an additional 3 high-risk chemotherapy blocks. Nineteen of the 106 treated patients met these criteria, with 14.2% (n = 15), being treated with HSCT. The other 91 patients received 2 years of treatment with dasatinib combined with chemotherapy.

Of the 81 patients evaluated for safety, grade 5 adverse events (AEs) occurred in 3 patients (4%), and 8 patients (10%) experienced AEs leading to treatment discontinuation, including fungal sepsis, hepatotoxicity of graft-versus-host disease, thrombocytopenia, CMV infection, pneumonia, nausea, enteritis and drug hypersensitivity. The most common serious AEs occurring in ≥10% of patients were pyrexia, febrile neutropenia, mucositis, diarrhea, sepsis, hypotension, infections, hypersensitivity, vomiting, renal insufficiency, abdominal pain and musculoskeletal pain.

“We recognize the urgency around developing and delivering therapies for children and young adults living with cancer, and today’s approval is an important example of our commitment to pediatric oncology,” said Jeffrey Jackson, PhD, development lead, hematology, Bristol-Myers Squibb, in a press release. “Building on our previous indication for children with Ph+ chronic myeloid leukemia in chronic phase, we’re pleased to bring Sprycel tablets to a second type of pediatric leukemia. This approval will give physicians another treatment option to offer appropriate pediatric patients with Ph+ ALL.”

The FDA initially approved dasatinib in November 2017 for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in chronic phase.

ALL represents 20% of all cancers diagnosed in patients aged less than 20 years, or more than 3000 new cases annually. Three percent of children who have ALL have Ph+ disease.

Reference
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Bristol-Myers Squibb. Published January 2, 2019. https://bit.ly/2F230c5?rel=0" . Accessed January 2, 2019.

This article originally appeared on OncLive® as “FDA Approves Dasatinib for Pediatric Ph+ ALL.”

 
By HenryLucas
May 06, 2020 12:15:06 pm
I haven't had a fungal infection but my mom who is not a diabetic has had one for years and the thing that has helped the most is blow drying her feet after every shower and use antifungal creams so that there is no moisture to feed the fungus. Also I used to have cracked feet from getting snow in my boots one winter and putting oil (almond, jojoba, coconut, etc.) has completely resolved that issue and since oil would probably suffocate the fungus as well it might be worth a try.
By Tysonwang
May 12, 2020 3:28:54 pm
Really this treatment looks so safe, but I have never tried any treatment like this, in fact, my uncle is also facing fungal infection, and due to skin allergy he can't use any chemical products, then I saw organic products on Ritecoupons, I bought it for him from there by using and now infection getting low day by day. Well if in future I need to take a treatment I will definitely prefer this one.
By waltercameron
May 20, 2020 1:50:19 am
Antifungal creams are important, but at the same time, som precautions should also be taken care of for these types of diseases. As, I am an associate of essaydone.co.uk I am glad that you are taking care of your mom who is also a diabetic patient, and therefore need more care. Diabetes kills a person slowly and that's why a diabetic patient should take care of themselves. IF we talk about FDA, I think they have done a great job by approving Dasatinib
By berenice6
May 21, 2020 2:47:15 am
Now order the first-class custom writing help in your subjects and topics via our knowledge and skilled expert writers of excellent online NVQ coursework writing service. We constantly deliver your educational work on time and our service fees are very inexpensive.
By saeed
May 27, 2020 3:16:32 am
By Imogen
May 30, 2020 4:47:00 am
Al giorno d'oggi tutti filtrano per la seduzione poich la vita finita per essere inclusa in modo fantastico. Inoltre mi sento incredibilmente stanco dopo aver lavorato tutto il giorno in ufficio. Per districarmi, suono un po giochi venerate come il pi inconfondibile macellaio. Sono contento di trovare un casino 20 euro e quasi tutti i miei amici ci giocano online. Questo reindirizzamento sbalorditivo per coinvolgere la tua psiche.
Reply
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.